A vaccine to prevent infections caused by Klebsiella pneumoniae
A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections
This study is testing a new vaccine designed to help protect people from serious infections caused by a tough bacteria called Klebsiella pneumoniae, and it aims to make the vaccine easier to produce while boosting your immune response.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vaxnewmo, LLC NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11094220 on NIH RePORTER |
What this research studies
This research focuses on developing a new vaccine to protect against Klebsiella pneumoniae, a bacteria that causes serious infections and is often resistant to antibiotics. The approach involves creating a multivalent conjugate vaccine that targets various strains of the bacteria, using a novel method called bioconjugation that simplifies the vaccine manufacturing process. By linking bacterial polysaccharides to carrier proteins, this vaccine aims to enhance the immune response and provide better protection against infections. Patients may be involved in trials to evaluate the vaccine's safety and effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at high risk for Klebsiella pneumoniae infections, such as those with weakened immune systems or those undergoing certain medical procedures.
Not a fit: Patients who are not at risk for Klebsiella pneumoniae infections or those who have already been vaccinated against it may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new vaccine that significantly reduces the incidence of Klebsiella pneumoniae infections, especially in vulnerable populations.
How similar studies have performed: Other research has shown success with similar conjugate vaccine approaches, indicating potential for this novel method to be effective as well.
Where this research is happening
Saint Louis, United States
- Vaxnewmo, LLC — Saint Louis, United States (Active)
Researchers
- Principal investigator: Harding, Christian — Vaxnewmo, LLC
- Study coordinator: Harding, Christian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.